The global atopic dermatitis treatment market will more than double in value from $3.6 billion in 2014 to an estimated $7.3 billion by 2024, representing a Compound Annual Growth Rate of 7.5%, according to a new report by GlobalData.
The increase, which will occur across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, will be driven primarily by the launch of the Sanofi/Regeneron’s dupilumab, the first biologic for the treatment of moderate-to-severe eczema. Dupilumab blocks IL-4 and IL-13, two cytokines required for the Th2 immune response and currently has breakthrough therapy designation from US Food and Drug Administration to treat adults with moderate-to-severe atopic dermatitis, who are not adequately controlled with topical prescription therapy and for whom these treatments are not appropriate. It is expected to contribute an estimated $3.8 billion to global sales by 2024.
Other key growth drivers in the space will be the continued uptake of topical calcineurin inhibitors, and the increased use of systemic therapies. The off-label use of Novartis’ Xolair is also expected to increase, albeit at a slower rate toward the end of the forecast period.